Susan C S Chong, Gene Lim, Kirsty Machon, Heather Mugwagwa, Jennifer Johnson, Roslyn Le Gautier, Jennifer Power
{"title":"Missing voices: building women living with HIV's meaningful engagement in HIV clinical and cure research.","authors":"Susan C S Chong, Gene Lim, Kirsty Machon, Heather Mugwagwa, Jennifer Johnson, Roslyn Le Gautier, Jennifer Power","doi":"10.1080/13691058.2024.2408353","DOIUrl":null,"url":null,"abstract":"<p><p>Women living with HIV are consistently under-represented in HIV clinical trials, including cure trials. Little is known about how cisgender women living with HIV in Australia perceive HIV cure research, their level of trust in research institutions/staff, and factors salient to participation in HIV cure trials. Semi-structured interviews were conducted with women living with HIV and clinicians working with women living with HIV to investigate motivations and barriers to gender-equitable representation in HIV clinical research. Participant motivations for participation included altruistic desires to benefit younger women, and to optimise resulting interventions. Women living with HIV expressed optimism that a cure would dispel HIV-related stigma and brings about substantial material improvement to their lives. Reluctance to participate related to concerns regarding potential side-effects, antiretroviral treatment interruption, and impacts on fertility. Unfamiliarity with trials, confidentiality concerns and logistical difficulties were also cited. Lastly, onerous eligibility criteria, clinicians' assumptions about women's willingness and ability to meaningfully provide consent to participation were cited as barriers which could be addressed. Bolstering women's participation in HIV cure research requires consideration of factors relating to reproductive health, analytical treatment interruption, and recruitment. Engaging women living with HIV in trial design and promotion may help overcome these issues.</p>","PeriodicalId":10799,"journal":{"name":"Culture, Health & Sexuality","volume":" ","pages":"1-17"},"PeriodicalIF":1.8000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Culture, Health & Sexuality","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13691058.2024.2408353","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"FAMILY STUDIES","Score":null,"Total":0}
引用次数: 0
Abstract
Women living with HIV are consistently under-represented in HIV clinical trials, including cure trials. Little is known about how cisgender women living with HIV in Australia perceive HIV cure research, their level of trust in research institutions/staff, and factors salient to participation in HIV cure trials. Semi-structured interviews were conducted with women living with HIV and clinicians working with women living with HIV to investigate motivations and barriers to gender-equitable representation in HIV clinical research. Participant motivations for participation included altruistic desires to benefit younger women, and to optimise resulting interventions. Women living with HIV expressed optimism that a cure would dispel HIV-related stigma and brings about substantial material improvement to their lives. Reluctance to participate related to concerns regarding potential side-effects, antiretroviral treatment interruption, and impacts on fertility. Unfamiliarity with trials, confidentiality concerns and logistical difficulties were also cited. Lastly, onerous eligibility criteria, clinicians' assumptions about women's willingness and ability to meaningfully provide consent to participation were cited as barriers which could be addressed. Bolstering women's participation in HIV cure research requires consideration of factors relating to reproductive health, analytical treatment interruption, and recruitment. Engaging women living with HIV in trial design and promotion may help overcome these issues.